for the Placebo Imaging Consortium IMPORTANCE Placebo effects reduce pain and contribute to clinical analgesia, but after decades of research, it remains unclear whether placebo treatments mainly affect nociceptive processes or other processes associated with pain evaluation.
P lacebo treatments are treatments with no intrinsic physical or pharmacological benefit. Nevertheless, they affect symptoms and physiology through patients' conceptions of the therapeutic context. 1, 2 Placebo effects can be elicited by sham treatments, but they are also a substantial and beneficial part of the overall response to verum treatments, including those involving drugs and/or surgery. 3, 4 In addition to conferring clinical benefits (and harms, in the case of nocebo effects), placebo effects reduce effect sizes for drug vs placebo differences in clinical trials, which may cause an increasing number of trials to fail 5 and thereby impede drug development. 6, 7 Thus there is an urgent need to better understand placebo effects and to develop biomarkers for active drug responses, as well as placebo responses, to improve decision making in early clinical trials. 8 Though placebo treatments can affect a variety of clinical outcomes, 9 placebo analgesia is the most robust and well studied. 7, 10, 11 Placebo analgesia has been linked with multiple psychological processes, including expectations and beliefs, 12 associative learning, 13 and social cognition. 14 Neurophysiological studies have suggested the involvement of descending inhibition of nociceptive afferents, with some studies supporting influences on spinal mechanisms [15] [16] [17] [18] [19] and others supporting higher-level cortical effects that cannot be explained by nociceptive input modulation alone, indicating affective or evaluative mechanisms. [20] [21] [22] [23] Nevertheless, the mechanisms by which placebo treatments change the perception of pain remain poorly understood, in part because of 2 limitations. First, previous studies were based on small sample sizes. Second, many brain areas associated with placebo analgesia, such as the anterior midcingulate cortex, the insula, and limbic regions, are involved in a range of functions, including cognitive decision making, 24 motor processes, 25 and emotion. 26, 27 Thus, previous studies have not been able to establish whether placebo analgesia affects nociception-associated and pain-associated processing specifically or other cognitive and affective processes associated with the multidimensional experience of pain. Recently, studies have begun to identify patterns of functional magnetic resonance imaging activity that yield objective and reliable 28, 29 brain measures associated with evoked pain. [30] [31] [32] [33] While they do not measure pain, which is by definition a subjective experience, they capture neurophysiological patterns associated with specific aspects of pain with high sensitivity. 34, 35 Among ongoing efforts, the neurologic pain signature (NPS) 33 is a measure that has been shown to reliably track the intensity of evoked experimental pain across multiple studies with high sensitivity while responding only minimally to nonpainful somatic stimuli and other salient, aversive events, thus exhibiting high specificity. [35] [36] [37] [38] [39] Although fully understanding the neurophysiological processes captured by the NPS is a matter of ongoing investigation, previous results suggest that the NPS predominantly reflects changes in nociceptive input and the pain that arises from it, while being insensitive to higher cognitive pain modulation. [36] [37] [38] [39] In this study, we harness these methodological advances in a systematic meta-analysis of single-participant data testing placebo effects on NPS responses. If placebo treatments predominantly affected early nociceptive processes, they would be expected to reduce activity in the NPS. If so, placebo effects and the endogenous pain-regulatory processes they engage may have pervasive effects on pain generation, making it hard to dissociate pain-associated and placebo-associated processes and outcomes. Conversely, if placebos mainly affect later-stage affective and evaluative processes, they may have little influence on NPS responses. In this case, it may be possible to develop meaningful measures of nociception that are placebo insensitive.
Methods
We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses of Individual Participant Data. 40 The study protocol and hypotheses were registered (https://osf.io /n9mb3/) on December 10, 2015, which was after eligibility criteria and study search were defined, but before data collection and analysis began.
Eligibility Criteria and Study Search
Criteria for study eligibility were peer-reviewed publication in the English language of an original investigation involving human participants who underwent functional neuroimaging of the brain during evoked pain and pain delivered under stimulus intensity-matched placebo and control conditions. Placebo treatment was defined as any condition where the experimental context suggested that an effective analgesic treatment was applied, including verbal suggestions and conditioning procedures that reinforced participants' expectations of reduced pain, 41 following the categorization of placebo paradigms introduced in Wager and Atlas in 2015.
the case of reanalyses with extended samples, 44, 45 we included the study with the largest sample. Studies with partially missing data were included and analyzed based on the available data.
46,47
Outcome Definition
We obtained NPS responses 33 for each individual participant in each experimental condition and contrasted pain and placebo with pain and nonplacebo control conditions. The NPS responses were calculated as the dot product of each image with the NPS pattern, yielding a weighted average of activity across the image, where the NPS specifies the weights. 33 High NPS responses reflect both higher similarity of the individual images with the NPS pattern and higher-magnitude functional magnetic resonance imaging activity in the specified pattern.
To keep baseline conditions of studies with within-participant crossover designs and between-group placebo manipulations comparable, we limited our analysis to posttreatment conditions; in other words, additional baseline measurements from withinparticipant or mixed-design studies were excluded.
46,48-50 Further, nonpainful 51 or low-intensity 43,46,48,52-54 stimulus conditions were excluded from analysis to maximize detection sensitivity for placebo effects. In several studies, images were provided for separate subconditions within placebo and control categories (eg, for leftlateralized and right-lateralized stimulation, 55 for strong and weak placebo conditions, 56, 57 or for early-heat-pain and lateheat-pain periods). 16, 57, 58 In these cases, we summarized the NPS responses by calculating an average response under placebo and under control treatment for each participant (details appear in eTable 2 in the Supplement). The scale of NPS responses depends on the scale of underlying imaging data and therefore on the image acquisition and analysis parameters used in the original studies. To avoid scaling issues, we based our analysis on the standardized effect size measure Hedges g, as is common in meta-analyses.
59
Similarly to the Cohen d, Hedges g is based on the mean difference between conditions divided by standard deviation, but with an additional correction for small sample bias. For withinparticipant studies we used Hedges g rm , which is based on the SD of within-participant differences corrected for withinparticipant correlations.
60,61

Risk of Bias Assessment
We used the Cochrane risk of bias tool 62 to evaluate the risk of bias for studies included in the present meta-analysis (details are in the eMethods and eTable 3 in the Supplement). We assessed biases from selection (which arises via insufficient randomization), performance (via insufficient blinding of participants or treatment providers), detection (via insufficient blinding of analysts), attrition (by missing data), reporting (via underreporting of nonsignificant studies), and sequence (which is potentially introduced by within-participant designs).
Analysis
Our main analysis followed a 3-part strategy. First, we tested the research question using all data available. Second, we conducted a conservative analysis excluding studies with high risk of bias. Third, we performed a responder analysis, in which we (1) only included participants who showed a behavioral placebo response (a pain report under placebo condition compared with the report under the control condition) above the study median, (2) excluded any experimental subconditions that may have diminished placebo effects (eg, placebo conditions deemed to be low efficacy or placebo conditions tested under pharmacological modulation), and (3) excluded any participants who were suspected outliers (the eMethods and eTable 2 in the Supplement). Effects were summarized across studies using the generic inverse-variance weighting method with DerSimonian and Laird random effects, 60 meaning studies were weighted by 1/SE 2 (where SE is the standard error). We estimated heterogeneity in results using the τ statistic, which represents the standard deviation of effect sizes between studies. 59 We tested against the null hypothesis of no effect at an error level of α < .05 (2-tailed), with additional inferences based on Bayes factors. 63 In brief, Bayes factors represent the relative likelihood of the null and the alternative hypotheses and have the advantage (compared with P values) that support for the null hypothesis can be concluded. Further analysis details and procedures used to check image quality are provided in the eMethods in the Supplement. Analysis was completed with MATLAB 2016b (MathWorks). The analysis code is available at https://github.com/mzunhammer /PlaceboImagingMetaAnalysis.
Results
Data Acquisition
We identified 96 published articles, of which 28 were selected as eligible. These included a total of 759 participants. Data from 20 studies and 603 participants were obtained, thus including the majority of eligible studies (71%) and participants (79.4%) published until 2015. Details on data acquisition are provided in eFigure 1 and eTable 1 in the Supplement. Eligible studies that could not be obtained were generally similar to the studies obtained in terms of pain stimulation, placebo induction, and study design; notably, 8 eligible studies with patient samples could not be obtained (eTable 4 in the Supplement). An update of the study search in March 2018 indicated that at least 6 eligible studies (with a combined patient population of 196 individuals) were published after data collection (in eMethods and eTable 1 in the Supplement). Even when considering these additional stud-ies, the present meta-analysis covers most eligible studies (59%) and participants (63.1%).
Risk of Bias
For pain ratings, the assessment of risk of bias (eResults, eTable 3, and eFigure 2 in the Supplement) indicated a high risk of performance (self-report) and detection bias, as well as unknown levels of reporting (publication) bias. For NPS responses, we found low risk of bias, because this measure does not depend on self-report and was unknown when the original studies were performed.
Sample Description
Included studies are listed in the Table, and key sample characteristics are shown in eFigure 3 in the Supplement. Details on pain stimulation, placebo treatment, image acquisition, and imaging analyses are provided in the eMethods and eTables 5, 6, 7, and 8 in the Supplement. Image alignment to Montreal Neurological Institute space was satisfactory, and the coverage of the voxels making up the NPS was near optimum levels (98.4% across all participants; eMethods and eFigure 4 in the Supplement). Four participants showed mean pain ratings less than 5% of the pain scale, indicating insufficient pain stimulation; evidence for imaging artifacts was found in 12 participants (2.0%) (eMethods in the Supplement). These participants were defined as outliers and excluded from the responder analysis, but retained in the primary and the conservative analysis.
NPS Responses to Painful Stimulation
The NPS responses to painful stimulation, compared with low-level baseline of placebo and control conditions pooled, 
Placebo Effects on Pain Ratings and NPS Responses
Placebo treatments, compared with matched control conditions, showed moderate 66 analgesic effects on pain ratings , indicating overwhelming support for the hypothesis of nonnull placebo effects on pain ratings. 63 Effect sizes varied considerably among studies (τ = 0.24), which may be explained by the variation in placebo paradigms used (Table; eTable Thus, placebo effects on the NPS were 12.1% as large as effects on pain ratings, and 3.7% as large as the effects of painful stimulation on the NPS. The Bayes factor was less than 1 (B N[0, 0.5] = 0.805), indicating that these data provide very weak support in favor of the null hypothesis of no effect. 
Associations Between Placebo Effects on Pain Reports and NPS Responses
For studies with crossover designs, which included withinparticipant testing of both placebo and control treatments, we performed a meta-analysis of within-study correlations between placebo effects on pain report and NPS responses across individuals. A Bayes factor of 894. 
Comparing Placebo Effects on the NPS With Effect of Reduced Stimulus Intensity
These findings suggest that the effects of placebo are small in terms of effective changes in nociceptive input. To further quantify placebo effects on the NPS in terms of equivalent . 68 These independent studies were used because stimulus intensities in our meta-analysis sample varied across individuals and produced behavioral effects several times larger than those of placebo, making estimation of equivalent stimulus intensity differences unreliable (for example, compare Figure 
Discussion
This large-scale meta-analysis of participant-level data revealed that placebo treatments have moderate effects on subjective reports of pain, but minimal effects on responses in the NPS, a central nervous system marker that tracks the intensity of nociceptive pain. These findings are based on most of the neuroimaging data on placebo analgesia published in the field until 2015. Results were consistent across a variety of paininduction and placebo-induction methods and across 3 parallel analyses varying in risk of bias, including an analysis limited to placebo responders. These results extend our understanding of placebo analgesia by suggesting that the effects of placebos on cerebral pain stimulus intensity processing are limited. We did observe small reductions in NPS response, which scaled with individual analgesia. Such effects may reflect descending inhibition of nociceptive systems, consistent with that findings of placebo, nocebo, and cognitive effects on spinal functional magnetic resonance imaging signals and brainstem nuclei involved in descending modulation that have been reported in previous studies. 15, [17] [18] [19] 70 However, the very small size of the effects on the NPS argues against a strong and pervasive early influence and point to stronger influences of other systems independent of the NPS. Our results emphasize that placebo analgesia is a phenomenon not based on a single mechanism but rather multiple mechanisms that have yet to be fully understood. Importantly, the NPS is not a complete model of pain and pain-associated functionality and was not intended as such. 33 Lack of effects on the NPS does not imply that placebo effects do not influence pain perception or pain-associated behavior. Indeed, the insensitivity of the NPS to manipulations that affect reported pain [35] [36] [37] [38] [39] implies that there must be other processes that contribute to pain report. However, the high sensitivity of the NPS to variation in nociceptive input (details may be found in Figure 1 ; eFigure 5 and eFigure 9 in the Supplement; and previous publications 33, [35] [36] [37] [38] [39] ), and its sensitivity to known analgesics (eg, the μ-opioid agonist remifentanil; eFigure10intheSupplement), suggest that if placebo treatments had pervasive early effects on pain processing, they should have been reflected in the NPS. They did not, leading us to infer that the placebo treatments studied here affect processes that are largely consequent to activation of nociceptive systems. Such processes include cognitive evaluation, 71 pain affect, pain-associated decisionmaking, and mesolimbic reward processing. 72 These processes are likely important for behavior and subjective well-being in their own right, and indeed, placebo treatments can impact long-term symptom perception and functionality in clinically meaningful ways, 73,74 whether they impact nociceptive pain signaling or not. These findings also have implications for the objective assessment of treatment effects on pain-associated neurophysiology. Patients evaluate their pain within a complex set of personal and cultural factors, 75 which poses challenges for clinical trials that use self-reported pain as a primary outcome. Whether patients feel better is paramount for overall well-being, but it does not guarantee that a treatment impacts the intended physiological mechanisms in the brain and elsewhere in the body. Objective neurophysiological measures do not replace reported pain and well-being, but they can provide measures of pharmacodynamic efficacy on specific brain targets. 8, 76 The present study further establishes the NPS as a brain measure that is sensitive to multiple types of evoked pain and insensitive to cognitive factors 33,35-39 in a large and geographically diverse sample. Because the NPS was found sensitive to opioid drugs but not placebo treatment, this may make it an appeal- 
Limitations
Several caveats deserve mention. First, this meta-analysis included only studies testing experimental placebo treatments for evoked pain in healthy participants. They may not generalize to clinical pain, which likely involves a complex mix of nociceptive and extranociceptive processes. 77 Second, we analyzed summary images from published analyses. While this helps to ensure careful quality control and is advantageous in ensuring broad generalizability of results, it likely increases interstudy heterogeneity and reduces overall effect sizes. However, these issues are unlikely to compromise our conclusions regarding placebo effects, because we compare them with strong positive controls. Third, the present metaanalysis only covers the relevant literature until mid-2015; more recent studies were not sought because of the time demands of collecting and analyzing participant-level imaging data. Advances in data sharing and standardization will hopefully make it possible to perform participant-level meta-analyses more quickly in the future. Importantly, not all placebo manipulations are likely to be equally effective, as indicated by the heterogeneity in placebo effects on pain ratings (as shown in Figure 2 and described in previous publications 10, 11 ). Although the studies tested here were fairly homogenous in terms of placebo effect on the NPS (Figure 3) , there are multiple pathways to cognitive pain modulation, 37,78 and some may affect the NPS more strongly than others. Treatment contexts not studied here may still influence NPS responses.
Conclusions
In sum, we have shown that placebo treatments have only small effects on a cerebral pattern tracking nociceptive pain in what is to our knowledge the largest meta-analysis of singleparticipant neuroimaging data on this topic to date. This suggests that placebo analgesia is largely mediated by networks different from those underlying the primary processing of noxious stimuli. Further studies are necessary to better understand which aspects of pain processing are affected by placebo treatments, and the significance of those processes for long-term clinical outcomes and wellbeing. This work serves as a starting point for the development of brain models that track pain-associated outcomes and other clinical and behavioral endpoints. This supplementary material has been provided by the authors to give readers additional information about their work. . Search results in these preceding peak-voxel-based meta-analyses were obtained by "identified using literature searches in PubMed and Google Scholar, the authors' personal libraries, and examining references of relevant papers." c) through recommendations by collaborating investigators.
eMethods. Supplementary Methods and Results
Original study identification
Studies identified are listed in eTable 1, the data-acquisition process is illustrated in eFigure 1.
Authors MZ, UB, and TW screened the titles and abstracts of all records retrieved; studies that provisionally met eligibility criteria were assessed for eligibility by examining the full text. Study eligibility was determined in a joint discussion of authors MZ, UB, and TW. Agreement between reviewers was accomplished in a joint discussion. There were no studies where the decision for inclusion/exclusion was a matter of ambiguity (see: eTable 1).
Post-hoc study identification:
An exploratory post-hoc literature search was performed on March 10 th 2018 to account for the fact that considerable time had passed between the initial study search and the completion of the meta-analysis. We searched pubmed and Thomson Reuters Web of Science from the beginning of 2015 to the present day using the following (extended) search terms: After removing duplicates, author MZ screened titles abstracts and assessed full-texts for eligibility. The posthoc analysis indicated that at least six eligible studies [3] [4] [5] [6] [7] [8] (with a total N of 196) were published after the initial study search in 2015 and therefore missed by the present meta-analysis (eTable 1).
Risk-of-bias-assessment
Aim of this risk-of-bias-assessment was to assess the studies included in our meta-analysis in terms of internal validity, regarding the effect of placebo interventions on (a) pain ratings and (b) neurologic pain signature (NPS) responses. Author MZ evaluated each study with respect to selection bias, performance bias, attrition bias, detection bias, report bias, and biases introduced by the use of within-subject designs (sequence effects) using to the Cochrane risk of bias tool 9 . All judgments were based on single-subject raw data, information taken from the published manuscripts, or personal communication with the study authors, following this order of priority. Studies with high risk of bias were excluded from the conservative analysis, but maintained in full and responder analyses.
Selection bias:
Problems due to non-random allocation are considered minor in within-subject designs as all participants undergo both treatments 10 . Therefore, risk of selection bias was low in most studies included, for both pain ratings and NPS responses. In summary, selection bias due to non-random allocation of participants to placebo/control conditions was judged as low for both ratings and NPS responses in most studies (eTable 3).
Performance bias:
Awareness of the allocated experimental condition by participants and personnel is considered the major source of performance bias in clinical trials 9 . However, the issue of blinding in experimental placebo research is different than in standard drug and device studies: Giving participants instructions that they are being treated and suggestions about treatment efficacy are core features of the placebo manipulation itself 11 . Further, the treatment provider and her/his behavior are considered major factors driving the placebo effect 12 . Placebo studies with blinded study participants or treatment providers 11 may underestimate the placebo effects typical for clinical settings. On the other hand, the fact that full blinding is conceptually difficult in experimental placebo studies does not imply that performance bias is not a problem 11 . The lack of blinding in placebo studies makes it difficult to discern placebo effects on core experiences and symptoms from placebo effects on participants' judgments and reporting behavior 11 . Thus, so-called "demand characteristics" (participants' tendency to report what they believe they should report, independent of experience) and other biases in judgment and decisionmaking can influence behavioral placebo effects, which is a major reason to also examine physiological outcomes. None of the included studies blinded participants or treatment providers (eTable 3), with the exception of one between-group study that blinded subjects in respect to group allocation 13 . The risk that pain ratings overestimate placebo effects on processes that contribute to core pain experiences (independent of judgments) is therefore high. However, physiological measures, including the NPS, are free of "demand characteristics". They may be influenced by evaluations and other cognitive processes or not, but they are direct readouts of physiology, not participants' beliefs. Further, the NPS has been shown to be insensitive to deliberate selfregulation of experimental pain (and pain ratings) in previous studies (e.g., 14 ). It is therefore unlikely that a lack of blinding affected NPS responses, systematically. We therefore conclude that the risk for performance bias through is low for NPS responses.
Detection bias:
It is a common problem in neuroimaging research that image pre-processing pipelines and statistical analysis involve numerous analysis choices. These do not only tempt analysts to cherry-pick favorable results (i.e., "Phacking"), but also pose a multiple comparison problem 15 . Blinding of analysts to the nature of experimental conditions and pre-specification of analysis parameters reduces this type of bias. No included study reported blinding of its analysts (eTable 3). We therefore judged the risk for detection bias as high for pain ratings, since allocated interventions and pain ratings were available to the original assessors. Moreover, the pre-processing pipelines and first-level models of imaging analyses varied considerably (eTable 8). Since our meta-analysis relies on the original first-level analyses, choices by the original analysts may affect NPS responses. Nevertheless, we rate the risk of detection bias for NPS response as low, since the weighting pattern underlying the NPS was not available to any author during the original analysis. It is therefore unlikely that choices in the original imaging analysis pipelines biased responses in the NPS for placebo vs. control conditions. We therefore judge the chance for over-estimating placebo effects on NPS responses due to detection bias as low.
Attrition bias:
Study drop-out and exclusion of participants may systematically affect study outcomes, especially when one experimental condition is affected more than another, or when participants are selected based on outcomes. eTable 3 provides a general overview on the amount of missing imaging data in respect to different experimental stages of the original studies. For one study 16 insufficient information was available to determine the amount of missing data. For the remaining studies, we found that our meta-analysis included 84% of participants included in the original studies before exclusions, 95% of participants successfully completing fMRI testing, and 99% of subjects included in the original analysis. Main reasons for the discrepancy between participants tested and participants completing measurements were problems with neuroimaging and pain stimulation equipment, which are unlikely to affect placebo effects systematically. Main reasons for the discrepancy between participants completing measurements and participants analyzed in the original studies were exclusions due to imaging artifacts and due to excessive head movements, which are also unlikely to affect placebo effects systematically. Data from 6 out of 16 subjects in one 17 and 2 out of 19 subjects in another study 18 were unavailable due to failure of data-storage media. Missing data for pain ratings was also missing for brain analyses, with the exception of Atlas et al. 2012 19 where pain ratings, but not imaging data, were lost for two subjects. Given the relatively low attrition rate and the fact that most studies are within-subject studies, where missing participants affect all experimental conditions alike, we conclude that attrition bias is unlikely to affect the outcomes of our meta-analysis.
Study reporting bias:
The underreporting of studies with non-significant ("negative") results is a prevailing problem in biomedical research 20 that has been suggested to affect experimental placebo research 11 . Underreporting of studies with nonsignificant behavioral placebo effects may inflate the effect sizes for pain ratings of the current meta-analysis. Again, for NPS responses, the risk of reporting bias was low, as the measure was not available when the studies were performed, initially. To assess the risk of reporting bias for pain ratings, we performed a funnel plot analysis based on the full sample 9 : The funnel plot (eFigure 2) and Eggert's regression test (p = .161) indicated no clear asymmetry and no clear relationship between study precision and effect size. However, the funnel plot showed no clear peak and 5 out of 20 studies were found to lie outside the range of 95% likelihood, which indicates that the heterogeneity in effect sizes was too large and/or the available range of standard errors was too small for reliable conclusions. Based on these results we conclude that the risk of study reporting bias was unknown for pain ratings and low for NPS responses. Other biases: unbalanced testing sequence in within-subject designs Sequence effects (e.g. habituation or sensitization) may confound treatment-effects in within-subject designs when the order of experimental conditions is not balanced or randomized. An overview on the sequence of treatment conditions in within-subject studies is provided in eTable 3. Raw data on the sequence of conditions was available for all but three studies. Two studies reported balanced testing 21 . No information about testing sequence was available for one study 22 . Several studies tested placebo and control conditions in an alternating fashion, reducing the risk of sequence confound 16, 17, [23] [24] [25] . Two studies tested placebo and control conditions in a fixed pre-placebo (control) vs. post-placebo sequence 18, 26 . These studies were excluded from conservative analysis. All remaining studies had balanced designs in respect to the sequence of placebo and control. Overall, sample imbalance for studies was low: placebo conditions were tested after control conditions in 54% of participants. Based on these figures we judged the overall risk of bias due to unbalanced sequence of testing as low.
Risk-of-bias summary:
In summary, we conclude high risk of bias for pain ratings. Main reason for this decision was the unresolved issues of distinguishing real placebo analgesia on primary symptom experiences vs. judgment and reporting biases, and the high risk of detection bias due to non-blinding of analysts. For NPS responses, we conclude that the risk of bias is low. The main reason for this decision was that the NPS response is a physiological measure that, while related to pain, is not directly affected by reporting and communication biases, and was unknown to the experimenters of the original studies at the time of publication.
A note on external validity:
The Cochrane risk-of bias tool focusses on the assessment of internal study validity. Beyond this tool, we identified an issue of external validity, that may affect the conclusions of the present meta-analysis. Two studies 21, 27 (accounting for 20.7% of the total sample, see: eTable 3) pre-selected placebo-responders. This practice constitutes no bias in terms of internal validity and merely limits the generalizability of results. However, mixing studies with and without responder-selection in a meta-analysis may entail an overrepresentation of placebo responders and therefore inflate effect size estimates. Therefore, these studies were excluded from conservative analysis, despite low risk of bias.
Analysis details: general
Correct data labeling was ascertained in correspondence with the original authors. All analyses were performed with MATLAB (v 2016b). Image pre-processing (re-slicing to a voxel size of 2x2x2 mm
3 ) was performed with SPM 12's imgcalc function. The CANlab toolbox was used to re-sample images to NPS-voxel space and to calculate NPS responses (www.github.com/canlab/CanlabCore). The meta-analysis was based on the algorithms used in Cochrane's RevMan 5 28 , implement as custom MATLAB functions. The complete analysis is available at: www.github.com/mzunhammer/PlaceboMetaAnalysis. For three within-subject studies 18, 21 , imaging data were available as contrasts images, representing precalculated differences between conditions. Consequently, within-subject correlations between experimental conditions could not be estimated for these studies. We therefore imputed the mean within-subject correlation using the average correlation observed across all other within-subject studies. Pearson's r was transformed to Fisher's-z for all inferential procedures. eFigure 1: CONSORT flowchart of data-acquisition * IPD for all eligible studies were sought. ** All available studies were analyzed.
eFigure 2: Funnel plot of placebo effects on pain ratings
Results based on full sample (n=603). The size of circles is proportional to number of study participants. Solid and dashed blue line denote the region in which 95% and 99% of studies are expected to lie in the absence of report bias and study heterogeneity. The shaded grey area denotes the area of non-significance under the null-hypothesis at = .05.
eFigure 3: Sample characteristics
Percentages shown are based on the number of participants in the full sample. All included studies were based on healthy populations and used visual analog scales (VAS) or numeric rating scales (NRS) to record pain ratings. All studies used blood oxygen level-dependent (BOLD) functional MRI imaging (fMRI), except for one arterial spin labeling (ASL) fMRI study 18 . Nonplacebo control conditions involved suggestions of ineffective treatment (14 studies), hidden treatment (3 studies) or no treatment at all (3 studies). Studies weighted according to inverse variance (IV); * excluded due to fixed testing sequence; ** excluded due to incomplete data-set; *** excluded due to pre-selection of placebo responders.
eFigure 7: Small effects of experimental placebo treatments on neurologic pain signature responses in placebo responders (responder analysis)
The analysis only included participants with a above-median behavioral placebo response (pain ratingplacebo -pain ratingcontrol), excluded any experimental sub-conditions that may have diminished placebo effects (e.g. "low efficacy" placebo conditions, or placebo conditions modulated by concomitant naloxone) and excluded any suspected outliers. Studies weighted according to inverse variance (IV); Note that the individual placebo response could not be determined in between-group studies. ~0.005 "An ascending series of stimuli were delivered in steps of 0.5 J, starting from very low intensities (0.5 J, below warmth threshold) until a mild-to-moderate pain intensity was achieved for each subject."
"[…]volunteers had to rate the perceived pain intensity, by rotating a knob which moved a cursor on a computerized visual analogue scale (VAS), anchored at 0 = no pain, and 100 = worst imaginable pain." Mild shock intensity was defined as the level of the shock just prior to the point at which participants acknowledged pain (mean = 1.44mA, sd = 0.85 mA). Intense shocks were set at the maximum level participants could tolerate (mean = 3.75 mA, sd = 2.34 mA).
"participants rated the intensity of the shock on a 10-point scale" -original pain ratings not available, only placebo-control contrast of ratings "pain intensity and unpleasantness ratings were assessed with a 15 cmplastic sliding visual analog scale (VAS) (Price et al., 1994) […]The minimum rating ("0") was designated as "no pain sensation" and "not at all unpleasant," whereas the maximum ("10") was labeled as "most intense pain sensation imag-inable" or "most unpleasant sensation imaginable," respectively." eTable 6: Placebo conditions in included studies * In analogy to the other studies open treatment were treated as "placebo conditions" and hidden treatment conditions as "control condition". Abbreviations: between, between-subject factor; A Sub-study 1; B Sub-study 2; IV, intravenous; within, within subject factor.
